Get to know our clinical trials

Trial to compare targeted intratumoral placement of phosphor-32 phosphor-32 (OncoSil) together with FOLFIRINOX and FOLFIRINOX chemotherapy as sole treatment in patients with locally advanced unresectable pancreatic adenocarcinoma.

Imagen del Dr. Mariano Ponz Sarvise, oncólogo médico de la Clínica Universidad de Navarra
Dr. Mariano Ponz-Sarvisé Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Liver and Pancreatic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • AN OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO COMPARE TARGETED INTRATUMORAL PLACEMENT OF PHOSPHOROUS-32 (ONCOSIL¿) IN CONJUNCTION WITH FOLFIRINOX (TRIPPFFX, ACRONYM FOR TARGETED INTRATUMOURAL PLACEMENT OF PHOSPHOROUS- 32 (ONCOSIL¿) IN ADDITION TO FOLFIRINOX) AND FOLFIRINOX CHEMOTHERAPY AS THE SOLE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC ADENOCARCINOMA.
  • Code EudraCT: -
  • Protocol number: ONCO01P04
  • Promoter: OncoSil Medical, Ltd.

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION